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Yonghong Li1, Wilson Liao2, Monica Chang1, Steven J. Schrodi1, Nam Bui1, Joseph J. Catanese1,
Annie Poon2, Nori Matsunami3, Kristina P. Callis-Duffin4, Mark F. Leppert3,5, Anne M. Bowcock6,7,8,
Pui-Yan Kwok2, Gerald G. Krueger3 and Ann B. Begovich1,9
Predisposition to psoriasis is known to be affected by genetic variation in HLA-C, IL12B, and IL23R, and although
other psoriasis-associated variants have been identified, incontrovertible statistical evidence for these markers
has not yet been obtained. To help resolve this issue, we tested 15 single-nucleotide polymorphisms (SNPs)
from 7 putative psoriasis-risk genes in 1,448 psoriasis patients and 1,385 control subjects; 3 SNPs, rs597980 in
ADAM33, rs6908425 in CDKAL1 and rs3789604 in PTPN22, were significant with the same risk allele as in prior
reports (one-sided Po0.05, false discovery rateo0.15). These three markers were tested in a fourth sample set
(599 cases and 299 controls); one marker, rs597980, replicated (one-sided Po0.05) and the other two had odds
ratios with the same directionality as in the original sample sets. Mantel–Haenszel meta-analyses of all available
case–control data, including those published by other groups, showed that these three markers were highly
significant (rs597980: P¼ 0.0057 (2,025 cases and 1,597 controls), rs6908425: P¼ 1.57 105 (3,206 cases and 4,529
controls), and rs3789604: P¼ 3.45 105 (2,823 cases and 4,066 controls)). These data increase the likelihood that
ADAM33, CDKAL1, and PTPN22 are true psoriasis-risk genes.
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INTRODUCTION
Psoriasis is a common, chronic, T-cell-mediated inflamma-
tory disease of the skin found in most ethnic groups, with a
prevalence of 1.5–3% in Caucasians and o1.0% in Asians
and Africans (Campalani and Barker, 2005). The disease is
characterized by an inflammatory process and marked
hyperproliferation of the epidermis, resulting in aberrant
terminal differentiation of keratinocytes. Psoriasis occurs
equally in men and women with B75% of patients
developing disease before the age of 40 years.
Twin studies suggest that approximately two-thirds of the
variation in psoriasis risk is heritable. Disease concordance in
monozygotic twins (65–72%) is higher than in dizygotic twins
(15–30%), and the incidence is substantially increased in
family members of affected individuals (e.g., 6% for first-
degree relatives) (Bowcock and Cookson, 2004). Specific
genetic variants, in the form of single-nucleotide polymorph-
isms (SNPs) and/or haplotypes in three genes, HLA-C, IL12B,
and IL23R, have been consistently associated with psoriasis
risk in multiple independent sample sets (Tsunemi et al.,
2002; Nair et al., 2006, 2008; Capon et al., 2007; Cargill
et al., 2007; Smith et al., 2007; Liu et al., 2008), and there is
increasing evidence that variants in the IL13/IL4 gene region
also contribute to psoriasis risk (Chang et al., 2008; Li et al.,
2008). However, the combined effects of these four loci do
not fully account for the heritability of this disease.
Additional genes in inflammatory and other pathways have
been implicated in the genetic etiology of psoriasis (Zhang et al.,
2007; Lesueur et al., 2007b; Capon et al., 2008; Hollox et al.,
2008; Liu et al., 2008; Smith et al., 2008; Wolf et al., 2008);
however, further testing in large, independent sample sets is
required to ascertain whether these findings represent genuine
associations. Here we tested 15 markers in 7 putative-risk gene
regions including ADAM33, IL15, SPATA2, CDKAL1, FLJ45139,
PTPN22, and a region on chr 1q24 in up to 2,047 individuals
with psoriasis and 1,684 control subjects. We provide meta-
analysis evidence from up to 3,206 cases and 4,529 controls
suggesting three may be true psoriasis susceptibility genes.
RESULTS
We genotyped 15 candidate markers from 7 distinct gene
regions in three white, North American psoriasis case–control
sample sets (sample sets 1–3) described in detail elsewhere
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(Cargill et al., 2007) (Table 1). These SNPs were chosen from
recent candidate gene-based or genome-wide association
studies; 13 markers were modestly associated with psoriasis
in these previous studies whereas 2 SNPs, not significant on
their own, were part of disease-associated haplotypes (Zhang
et al., 2007; Lesueur et al., 2007b; Capon et al., 2008; Smith
et al., 2008; Wolf et al., 2008) (for details see ‘‘Materials and
Methods’’).
Genotype distributions in our sample sets showed no
consistent or pronounced violation of Hardy–Weinberg
equilibrium in either cases or controls (all Hardy–Weinberg
equilibrium P40.01) except for g.96516 (P¼0.003 in
sample set 2 cases) (Supplementary Table 1). The allele
frequencies of all markers were similar to previous reports
except for two IL15 SNPs, rs10519613 and g.96516. SNP
g.96516, the most significant marker in the Chinese case–-
control study (Zhang et al., 2007) with a control minor allele
frequency of 23%, was rare in our white samples (minor
allele frequency¼0.4%), which is consistent with findings in
another white sample set (Weger et al., 2008).
We tested association of these SNPs with psoriasis risk
using the same genetic model suggested in the original
report—13 SNPs at the single marker level and 2 purported
haplotypes in ADAM33 and IL15. Because our individual
sample sets had low power to replicate markers with a weak
effect, we evaluated replication in the three sample sets
combined (1,448 psoriasis patients and 1,385 control
subjects). On the basis of a Mantel–Haenszel analysis, three
markers replicated (one-sided Po0.05): rs597980 in
ADAM33, rs6908425 in CDKAL1, and rs3789604 in PTPN22
(Table 2). This is more than one would expect under the null
hypothesis (13 markers tested0.05¼B1 marker), suggest-
ing that some of these significant SNPs are likely to be
genuine psoriasis markers. These three SNPs all had a false
discovery rate of less than 0.15, indicating that one in six of
these markers may be false positive (Table 2).
Although the ADAM33 SNP, rs597980, was significant,
the three-marker ADAM33 haplotype (defined by rs512625,
rs2280089, and rs535964), which showed the most signifi-
cant association in the original report (P¼0.00004) (Lesueur
et al., 2007b), was not significant in our sample sets (best
haplotype P¼0.28, global P¼ 0.34). Similarly, we did not
observe significant association of the four marker
(rs10519613, g.96516, rs1057972, and rs10833) IL15 haplo-
type in our sample sets (best haplotype P¼0.37, global
P¼0.52), even though this haplotype was associated with
both psoriasis and increased IL15 transcriptional activity in
the Chinese case–control study (Zhang et al., 2007).
Next, we tested the three replicated SNPs in a fourth sample
set consisting of 599 psoriasis cases and 299 controls. The
ADAM33 marker replicated (one-sided P¼ 0.031), and,
although the other two markers were not significant in this
sample set, the directionality of the odds ratios was the same as
reported in the original sample sets (Table 3). A Mantel–
Haenszel analysis of our four psoriasis sample sets combined,
showed that all three SNPs were significant (one-sided
Po0.05). A meta-analysis of the CDKAL1 and PTPN22markers
in our replication sample sets plus the original case–control
reports showed that both were highly significant (rs6908425:
P¼ 1.57105 and rs3789604: P¼ 3.45105). Because the
initial study of ADAM33 was family-based, we could not carry
out a meta-analysis for rs597980.
Table 1. Genotyped markers
Associated disease
in prior studies Publication
Putative risk
gene/region SNP ID Chr Position (bp)1 SNP type
Psoriasis Lesueur et al. (2007b) ADAM33 rs512625 20 3,596,378 Intergenic
rs677044 20 3,597,431 30-UTR2
rs2280089 20 3,598,127 Intron
rs597980 20 3,599,165 Intron
rs44707 20 3,599,226 Intron
Zhang et al. (2007) IL15 rs10519613 4 142,873,534 30UTR
g.96516 4 142,873,720 30UTR
rs1057972 4 142,873,882 30UTR
rs10833 4 142,873,997 30UTR
Capon et al. (2008) SPATA2 rs495337 20 47,955,737 Synonymous
Smith et al. (2008) PTPN22 rs1217414 1 114,214,190 Intron
rs3789604 1 114,156,465 Synonymous
Psoriasis/Crohn’s disease Wolf et al. (2008) 1q24 rs12037606 1 171,165,025 Intergenic
CDKAL1 rs6908425 6 20,836,710 Intron
FLJ45139 rs2836754 21 39,213,610 Intron
SNP, single-nucleotide polymorphism; 30-UTR, 30-untranslated region.
1Positions according to genomic contig NT_011387.8 (Entrez Nucleotide) in the National Center for Biotechnology Information Genome Build 36.3.
230 untranslated region.
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DISCUSSION
These results suggest that variants in three distinct genes may
be associated with psoriasis risk. Although evidence of
replication for individual SNPs in our combined sample sets
was modest (one-sided P¼0.0057–0.015), the overall ob-
servation is significant in the context of our study design—
these three markers had false discovery rates o0.15
suggesting at least two may be considered true positives.
Furthermore, two of the three markers were highly significant
in a meta-analysis of all sample sets combined
(P¼1.57105 and 3.45105). The observed effect sizes
for the three variants, however, were modest, with odds ratios
all less than 1.25. This is typical of other recently identified
genetic variants that make incremental contributions to
disease risk in common, complex disorders (Wellcome Trust
Case Control Consortium, 2007; Barrett et al., 2008;
Raychaudhuri et al., 2008).
Given that all three variants are relatively frequent (control
allele frequency 40.20), their population attributable risk
cannot be discounted if these findings withstand replication
in other sample sets. For example, assuming that the odds
ratio and control allele frequency observed in the meta-
analysis are correct, the allelic population attributable risk for
the CDKAL1 marker would amount to 13.7%. Furthermore,
carrying multiple-risk markers in these and the other four
well-established genes, HLA-C, IL12B, IL23R, and IL13/IL4 is
expected to substantially augment an individual’s suscept-
ibility to psoriasis; conversely, individuals with multiple
protective alleles may be at much reduced risk.
The association of these three markers with psoriasis
further supports the observation of pleiotropic effects in
inflammatory diseases—ADAM33 has been proposed
as a risk factor for asthma (Van Eerdewegh et al., 2002),
CDKAL1 for Crohn’s disease (Wellcome Trust Case Control
Consortium, 2007) and type 2 diabetes (Steinthorsdottir
et al., 2007), and PTPN22 for rheumatoid arthritis, type I
diabetes and others (Begovich et al., 2004; Bottini et al.,
2004; Gregersen et al., 2006). It should be noted, however,
that the PTPN22 variant associated with psoriasis risk is
different from the major variant (R620W missense SNP)
associated with rheumatoid arthritis and other diseases;
previous studies have shown that R620W is not significantly
associated with psoriasis in our sample sets (unpublished
results) or other sample sets (Criswell et al., 2005; Nistor
et al., 2005; Huffmeier et al., 2006). These findings are
consistent with evidence suggesting variants in noncoding
regions of the PTPN22 gene region are involved in psoriasis
(Huffmeier et al., 2006).
Interpretation of our negative results for the other putative
psoriasis-risk variants should take into account various factors
such as the overall sample size, marker effect sizes, the allele
frequencies of the tested markers, and the possibility of
genetic heterogeneity. Our three combined sample sets
(1,448 cases and 1,385 controls) have 480% power to
replicate allelic association for a marker with a X0.20
control allele frequency, as is the case for 11 out of the 13
markers tested here, and an odds ratio of 1.2. However, our
three combined sample sets have less than 50% power to
replicate markers with odds ratio of 1.1 or less, regardless of
marker allele frequency. Not surprisingly, all three significant
markers identified in this study had odds ratio X1.1 in our
sample sets.
Table 2. Association test of putative psoriasis risk markers in the three sample sets combined
Gene/region SNP Minor allele
Major
allele
Case allele
frequency
Control allele
frequency OR (95% CI) Allelic P1 FDR2
ADAM33 rs5126253 A G 0.298 0.310 0.94 (0.84–1.06) 0.176 0.286
ADAM33 rs677044 G A 0.213 0.211 1.01 (0.89–1.14) 0.572 0.620
ADAM33 rs597980 A G 0.475 0.450 1.10 (0.99–1.22) 0.030 0.136
ADAM33 rs44707 G T 0.389 0.409 0.92 (0.82–1.02) 0.068 0.176
IL15 rs10519613 A C 0.096 0.093 1.03 (0.86–1.23) 0.366 0.433
IL15 g.96516 T A 0.0014 0.004 0.34 (0.11 –1.09) 0.0580 0.176
IL15 rs1057972 T A 0.472 0.476 0.98 (0.88–1.09) 0.626 0.626
SPATA2 rs495337 A G 0.388 0.393 0.97 (0.88–1.09) 0.354 0.433
1q24 rs12037606 A G 0.420 0.406 1.05 (0.95–1.17) 0.155 0.286
CDKAL1 rs6908425 T C 0.200 0.220 0.88 (0.77–1.00) 0.031 0.136
FLJ45139 rs2836754 T C 0.383 0.368 1.06 (0.95–1.18) 0.123 0.265
PTPN22 rs1217414 A G 0.276 0.266 1.05 (0.93–1.18) 0.204 0.295
PTPN22 rs3789604 G T 0.184 0.208 0.86 (0.75–0.98) 0.013 0.136
SNP, single-nucleotide polymorphism; FDR, false discovery rate.
Markers with Po0.05 in boldface.
1One-sided, based on previous studies except for g.96516 whose allele frequencies were markedly different between the White and Asian populations.
2false discovery rate.
3rs512625 was recently reported to be significant in another case–control study (Siroux et al., 2008). A meta-analysis of this marker in our three sample sets
and that of Siroux et al. showed that this SNP was not significant (Mantel–Haenszel Pcombined=0.27, ORcombined=0.94 (95% CI: 0.85–1.05), Breslow–Day test
for OR homogeneity P=0.99).
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In conclusion, our data suggest that three genes, ADAM33,
CDKAL1, and PTPN22, in addition to HLA-C, IL12B, IL23R,
and IL13/IL4, may be psoriasis-risk factors. Given the modest
effect sizes, further replication, followed by a meta-analysis,
is required to confirm or refute these hypotheses and detailed
fine mapping is required to pinpoint the causal variants. In
addition, although we did not observe significant association
of the other tested markers with psoriasis, we cannot rule out
their involvement in the genetics of the disease, due to the
modest power of our sample sets to detect small effect sizes.
An unequivocal identification of unreported genetic risk
factors should further our understanding of the underlying
disease mechanism, provide fresh leads to drug discovery,
and identify potential pharmacogenomic markers.
MATERIALS AND METHODS
Marker selection
The primary goal of this study was to replicate 15 genetic variants
recently reported to be associated with psoriasis risk (see Table 1 for
the complete list of SNPs).
ADAM33. Having confirmed the presence of a psoriasis suscept-
ibility locus on chromosome 20p13 in a linkage study (Lesueur et al.,
2007a), Lesueur et al. (2007b) fine mapped a 17Mb region using a
family-based association study and identified ADAM33 as the
putative psoriasis-risk gene. Five of the tested SNPs reached
significance (P¼ 0.01–0.04) and testing combinations of SNPs
revealed a three-SNP haplotype that was highly significant
(P¼ 0.0009). Although these findings were not replicated in a
second smaller family-based sample set (all P40.05) (Lesueur et al.,
2007b), a recent French study replicated association of one
ADAM33 SNP, rs512625, with psoriasis (Siroux et al., 2008).
IL15. Employing a candidate gene approach, Zhang et al. (2007)
tested 12 SNPs in the IL15 gene, which lies within the PSORS9 locus
on chromosome 4q31.2–q32.1, in a Chinese case–control sample set
(632 psoriasis patients/485 control subjects). Four markers were
significant (Po0.05), with a reported 30-untranslated region (UTR)
SNP (g.96516A-T) showing the strongest association
(Pcorrection¼ 0.00006). Two haplotypes containing the minor T allele
of g.96516 were highly correlated with disease susceptibility and
Table 3. Association test and meta-analysis of the three replicated markers with psoriasis risk in the fourth sample
set and all case–control sample sets investigated
Case Control
Gene SNP Sample set 11 12 22 Sum MAF 11 12 22 Sum MAF Allelic P1 OR (95%CI)2
ADAM33 rs5979803 SS1 98 243 117 458 0.479 105 217 136 458 0.466 0.287 1.05 (0.87–1.26)
SS2 126 220 147 493 0.479 101 237 154 492 0.446 0.074 1.14 (0.95–1.36)
SS3 105 240 137 482 0.467 82 208 136 426 0.437 0.099 1.12 (0.93–1.35)
SS4 119 292 181 592 0.448 41 93 87 221 0.396 0.031 1.23 (0.98–1.54)
SS1+2+3+4 448 995 582 2,025 0.467 329 755 513 1,597 0.442 0.0057 1.13 (1.02–1.24)
CDKAL1 rs6908425 SS1 21 135 309 465 0.190 26 150 281 457 0.221 0.052 0.82 (0.66–1.03)
SS2 18 147 327 492 0.186 23 175 294 492 0.225 0.017 0.78 (0.63–0.98)
SS3 18 179 285 482 0.223 26 130 270 426 0.214 0.686 1.05 (0.84–1.32)
SS4 14 177 397 588 0.174 13 65 144 222 0.205 0.077 0.81 (0.62–1.07)
SS1+2+3+4 71 638 1,318 2,027 0.192 88 520 989 1,597 0.218 0.010 0.87 (0.77–0.97)
UK4 46 360 773 1,179 0.192 165 1,018 1,749 2,932 0.230 1.52E04 0.79 (0.70–0.89)
SS1+2+3+4+UK 117 998 2,091 3,206 0.192 253 1,538 2,738 4,529 0.226 1.57E05 0.83 (0.76–0.90)
PTPN22 rs3789604 SS1 10 136 315 461 0.169 23 152 284 459 0.216 0.0057 0.74 (0.58–0.93)
SS2 21 161 311 493 0.206 17 177 298 492 0.214 0.321 0.94 (0.76–1.17)
SS3 15 140 327 482 0.176 14 135 277 426 0.191 0.205 0.90 (0.71–1.14)
SS4 14 159 379 552 0.169 13 52 154 219 0.178 0.341 0.94 (0.70–1.25)
SS1+2+3+4 60 596 1,332 1,988 0.180 67 516 1,013 1,596 0.204 0.016 0.87 (0.77–0.98)
UK5 23 199 613 835 0.147 84 765 1,621 2,470 0.189 9.94E05 0.73 (0.63–0.86)
SS1+2+3+4+UK 83 795 1,945 2,823 0.170 151 1,281 2,634 4,066 0.195 3.45E05 0.81 (0.74–0.89)
1Calculated by w2 method for individual sample sets and by Mantel Haenszel method for the combined sample sets; two sided for UK and SS1+2+3+4+UK
and one sided for all other replication sample sets, individually or combined.
2Calculated by w2 method for individual sample sets and by Mantel Haenszel method for the combined sample sets.
3Prior study used family-based samples; not included for meta-analysis.
4Wolf et al. (2008).
5Smith et al. (2008).
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increased IL15 transcriptional activity. IL15, a proinflammatory
cytokine affecting T-cell activation and proliferation, is involved in
regulation of inflammatory events in several diseases including
psoriasis (McInnes and Gracie, 2004). In addition, targeting the IL15
protein was efficacious in alleviating psoriasis pathology in an
animal model (Villadsen et al., 2003).
SPATA2. In a genome-wide association study testing 408,000
SNPs, Capon et al. (2008) identified strong association of a reported
SNP, rs495337, with psoriasis risk (P¼ 1.4 108, 2,679 cases and
2,215 controls). rs495337 maps to the SPATA2 transcript and is in
perfect linkage disequilibrium with several SNPs in the adjacent
ZNF313 gene. On the basis of the association of rs495337
with ZNF313 expression and a potential role for ZNF313 in
regulating T-cell activation, ZNF313 was proposed as a risk factor
for psoriasis.
CDKAL1, FLJ45139, and chr 1q24. Given that psoriasis and
Crohn’s disease share a common genetic etiology (Duerr et al.,
2006; Cargill et al., 2007), Wolf et al. (2008) tested in their psoriasis
sample set (1,256 cases/2,938 controls) 15 Crohn’s disease-
associated SNPs and reported that three may be involved in psoriasis
(rs12035082 in 1q24, P¼ 0.009; rs2836754 in FLJ45139 on
21q22.2, P¼ 0.002; rs6908425 in CDKAL1 on 6p22.3,
P¼ 0.00015). We tested rs2836754 and rs6908425 and
rs12037606, a proxy for rs12035802 (r2¼ 1, in the CEU samples;
www.hapmap.org).
PTPN22. Smith and colleagues recently tested whether variants in
PTPN22, a widely recognized risk factor for retinoic acid (Begovich
et al., 2004) and several other autoimmune diseases (Bottini et al.,
2004; Criswell et al., 2005), were also associated with psoriasis
(Smith et al., 2008). Although the retinoic acid-associated rs2476601
(R620W) SNP was not significant in their psoriasis sample set,
agreeing with other reports (Criswell et al., 2005; Nistor et al., 2005;
Huffmeier et al., 2006), they found that two other SNPs, rs1217414
and rs3789604, were significantly associated with early onset
disease (P¼ 0.003 and 0.0002, respectively; 647 cases vs 566
controls).
Clinical samples
Three white, North American psoriasis sample sets, totaling 1,448
individuals with dermatologist-confirmed psoriasis (cases) and 1,385
normal subjects (controls), have been described in detail elsewhere
(Cargill et al., 2007). Briefly, sample set 1, obtained from the
University of Utah, consisted of 467 cases and 460 controls. Sample
set 2, obtained from the Genomics Collaborative Division of
SeraCare Life Sciences, consisted of 498 cases and 498 controls.
Sample set 3 consisted of 483 cases and 427 control subjects; 293 of
the cases and 292 of the controls were provided by Genomics
Collaborative; BioCollections Worldwide provided the rest. All
individuals were 18 years or older at the enrollment.
The fourth case–control sample set included 599 unrelated
Caucasian patients of European descent recruited from outpatient
clinics at the University of California, San Francisco and Washington
University, St. Louis, MO. All subjects filled out a clinical
questionnaire and received a skin examination by a dermatologist,
who confirmed the diagnosis of plaque psoriasis. Controls (n¼ 299)
were unrelated white individuals of European descent recruited in
San Francisco, who had no history of psoriasis, autoimmune disease,
or cancer.
Clinical research was conducted according to the Declaration of
Helsinki Principles. All protocols were approved by national and/or
local institutional review boards and informed written consent was
obtained from all subjects.
Genotyping
Genotyping of SNPs in sample sets 1–3 was carried out by allele-
specific real-time PCR, with accuracy 499% (Chang et al., 2008).
For sample set 4, rs597980 (ADAM33) and rs6908425 (CDKAL1)
were genotyped by TaqMan, (Applied Biosystems, Foster City, CA,
USA) and rs3789604 (PTPN22) by sequencing.
Statistical analysis
Hardy–Weinberg equilibrium testing was performed using the
exact test of Weir (Weir, 1996). Allelic association of SNPs with
psoriasis risk was determined by the w2-test in individual sample sets
and by meta-analysis using fixed effects of Mantel–Haenszel
methods. Haplotypes were inferred from the genotypic data, and
haplotype frequencies estimated and tested for association
with disease status using a score test with haplotypes coded in
an additive fashion (Schaid et al., 2002). Power of replication
was estimated using the PS:Power and Sample Size Calculation
Program (http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/Power
SampleSize). False discovery rate (Benjamini and Hockberg, 1995),
was estimated using one-sided P-values obtained in the combined
sample sets.
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